BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 10965094)

  • 1. Time-kill studies of antimicrobial combinations including cefotaxime, ceftriaxone, vancomycin and meropenem against cephalosporin-resistant Streptococcus pneumoniae.
    Kim BN; Woo JH; Kim YS; Ryu J; Kim MN; Pai CH
    Chemotherapy; 2000; 46(5):303-8. PubMed ID: 10965094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.
    Fitoussi F; Doit C; Benali K; Bonacorsi S; Geslin P; Bingen E
    Antimicrob Agents Chemother; 1998 Apr; 42(4):942-4. PubMed ID: 9559815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.
    Ribes S; Taberner F; Domenech A; Cabellos C; Tubau F; Liñares J; Viladrich PF; Gudiol F
    J Antimicrob Chemother; 2006 May; 57(5):931-6. PubMed ID: 16507562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.
    Friedland IR; Paris M; Ehrett S; Hickey S; Olsen K; McCracken GH
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1630-6. PubMed ID: 8215275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant Streptococcus pneumoniae ATCC 51916.
    Ribes S; Taberner F; Domenech A; Cabellos C; Tubau F; Liñares J; Fernández Viladrich P; Gudiol F
    J Antimicrob Chemother; 2005 Nov; 56(5):979-82. PubMed ID: 16174686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae.
    Cormican MG; Erwin ME; Jones RN
    Diagn Microbiol Infect Dis; 1995; 22(1-2):119-23. PubMed ID: 7587024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain.
    Gerber CM; Cottagnoud M; Neftel KA; Täuber MG; Cottagnoud P
    Eur J Clin Microbiol Infect Dis; 1999 Dec; 18(12):866-70. PubMed ID: 10691197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-kill evaluation of antimicrobial regimens against clinical isolates of penicillin-resistant Streptococcus pneumoniae.
    Bañón Arias R; García López M; Pinedo Sánchez A
    J Chemother; 2001 Oct; 13(5):535-40. PubMed ID: 11760218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro bactericide activity of different antibiotic combinations to Streptococcus pneumoniae resistant to penicillin and cefotaxime].
    Tubau F; Liñares J; Ardanuy C; Martínez-Lacasa J; Fernández A; Cabellos C; Fernández-Viladrich P; Martín R
    Enferm Infecc Microbiol Clin; 1996 Dec; 14(10):590-5. PubMed ID: 9053000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of Streptococcus pneumoniae strains to nine beta-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin.
    Marton A; Major P
    Microb Drug Resist; 1996; 2(3):361-9. PubMed ID: 9158796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae.
    Pikis A; Donkersloot JA; Akram S; Keith JM; Campos JM; Rodriguez WJ
    J Antimicrob Chemother; 1997 Jul; 40(1):105-8. PubMed ID: 9249211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacteriologic outcome of children with cefotaxime- or ceftriaxone-susceptible and -nonsusceptible Streptococcus pneumoniae meningitis.
    Olivier C; Cohen R; Begué P; Floret D
    Pediatr Infect Dis J; 2000 Oct; 19(10):1015-7. PubMed ID: 11055609
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels.
    Stratton CW; Aldridge KE; Gelfand MS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):35-42. PubMed ID: 7587048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of cefditoren against clinical isolates of penicillin-susceptible and resistant strains of Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis.
    Fernández-Roblas R; López JC; Ramos JM; Gimeno M; Coronel P; Soriano F
    J Antimicrob Chemother; 1996 May; 37(5):1038-9. PubMed ID: 8737159
    [No Abstract]   [Full Text] [Related]  

  • 15. Two cases of bacterial meningitis due to meropenem-resistant Streptococcus pneumoniae: A threat of serotype 35B, ST 558 lineage.
    Yamada N; Nakamoto T; Takei H; Shoji T; Takahashi K; Sato J; Takeuchi N; Ohkusu M; Ishiwada N
    J Infect Chemother; 2020 Jul; 26(7):745-748. PubMed ID: 32171658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.
    Tan TQ; Schutze GE; Mason EO; Kaplan SL
    Antimicrob Agents Chemother; 1994 May; 38(5):918-23. PubMed ID: 8067771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampicin+ceftriaxone versus vancomycin+ceftriaxone in the treatment of penicillin- and cephalosporin-resistant pneumococcal meningitis in an experimental rabbit model.
    Suntur BM; Yurtseven T; Sipahi OR; Buke C; Buke M
    Int J Antimicrob Agents; 2005 Sep; 26(3):258-60. PubMed ID: 16099624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.
    Fitoussi F; Doit C; Geslin P; Bingen E
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2372-5. PubMed ID: 10508009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis.
    Fernández A; Cabellos C; Tubau F; Maiques JM; Doménech A; Ribes S; Liñares J; Viladrich PF; Gudiol F
    J Antimicrob Chemother; 2005 Jan; 55(1):78-83. PubMed ID: 15546968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.
    Gums JG; Boatwright DW; Camblin M; Halstead DC; Jones ME; Sanderson R
    Ann Pharmacother; 2008 Jan; 42(1):71-9. PubMed ID: 18094350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.